NI201800006A - Agentes, usos y métodos para el tratamiento de la sinucleinopatía - Google Patents

Agentes, usos y métodos para el tratamiento de la sinucleinopatía

Info

Publication number
NI201800006A
NI201800006A NI201800006A NI201800006A NI201800006A NI 201800006 A NI201800006 A NI 201800006A NI 201800006 A NI201800006 A NI 201800006A NI 201800006 A NI201800006 A NI 201800006A NI 201800006 A NI201800006 A NI 201800006A
Authority
NI
Nicaragua
Prior art keywords
disease
parkinson
sinucleinopathy
agents
treatment
Prior art date
Application number
NI201800006A
Other languages
English (en)
Inventor
Kallunki Pekka
Fog Karina
Buur Vesterager Louise
Bergström Ann-Louise
Sotty Florence
Satijn David
Van Den Brink Edward
Parren Paul
Rademaker Rik
Vink Tom
John Malik Ibrahim
Christina Pereira Montezinho Liliana
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of NI201800006A publication Critical patent/NI201800006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Abstract

La invención se refiere a nuevos anticuerpos anti-alfa-sinucleína monoclonales. Los anticuerpos pueden usarse para tratar una sinucleinopatía tal como la enfermedad de Parkinson (incluyendo formas idiopáticas y hereditarias de enfermedad de Parkinson), Enfermedad Difusacon Cuerpos de Lewy(DLB), variante de enfermedad de Alzheimer con cuerpos de Lewy (LBV), enfermedad Combinada de Alzheimer y Parkinson, fallo autonómico puro y atrofia multisistema.
NI201800006A 2015-07-13 2018-01-11 Agentes, usos y métodos para el tratamiento de la sinucleinopatía NI201800006A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1512203.9A GB201512203D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods

Publications (1)

Publication Number Publication Date
NI201800006A true NI201800006A (es) 2018-10-18

Family

ID=54013851

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201800006A NI201800006A (es) 2015-07-13 2018-01-11 Agentes, usos y métodos para el tratamiento de la sinucleinopatía

Country Status (33)

Country Link
US (12) US10800836B2 (es)
EP (1) EP3322722A1 (es)
JP (3) JP7012004B2 (es)
KR (1) KR20180029205A (es)
CN (2) CN107709361A (es)
AR (1) AR105336A1 (es)
AU (1) AU2016292896B2 (es)
BR (1) BR112017027506A2 (es)
CA (1) CA2989735A1 (es)
CL (1) CL2018000075A1 (es)
CO (1) CO2017012941A2 (es)
CR (2) CR20180021A (es)
DO (1) DOP2018000013A (es)
EA (1) EA036499B1 (es)
EC (1) ECSP18002645A (es)
GB (1) GB201512203D0 (es)
GE (1) GEP20207151B (es)
HK (1) HK1254358A1 (es)
IL (1) IL256501B (es)
JO (1) JO3692B1 (es)
MA (1) MA42439A (es)
MX (1) MX2018000504A (es)
MY (1) MY194944A (es)
NI (1) NI201800006A (es)
PE (1) PE20181049A1 (es)
PH (1) PH12018500016A1 (es)
RU (1) RU2765303C2 (es)
SV (1) SV2018005612A (es)
TN (1) TN2018000005A1 (es)
TW (1) TWI729992B (es)
UA (1) UA125501C2 (es)
WO (1) WO2017009312A1 (es)
ZA (1) ZA201708607B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
KR102593669B1 (ko) * 2016-11-15 2023-10-25 하. 룬드벡 아크티에셀스카브 시누클레인병증의 치료를 위한 제제, 용도 및 방법
MA47019A (fr) 2016-12-16 2021-04-21 H Lundbeck As Agents, utilisations et procédés
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
SG11201906947SA (en) 2017-02-17 2019-08-27 Bristol Myers Squibb Co Antibodies to alpha-synuclein and uses thereof
US10799484B2 (en) 2017-03-27 2020-10-13 Chase Therapeutics Corporation Compositions and methods for treating synucleinopathies
WO2018204352A1 (en) 2017-05-01 2018-11-08 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
WO2019040617A1 (en) 2017-08-23 2019-02-28 The Trustees Of The University Of Pennsylvania MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHODS USING SAME
JP7173618B2 (ja) * 2017-11-17 2022-11-16 エービーエル バイオ インコーポレイテッド アルファ－シヌクレインに対する抗体およびその用途
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
AU2019211435A1 (en) * 2018-01-26 2020-07-30 Quantum-Si Incorporated Machine learning enabled pulse and base calling for sequencing devices
WO2019157527A2 (en) * 2018-02-12 2019-08-15 The Scripps Research Institute Methods related to parkinson's disease and synucleinopathies
AU2019318195A1 (en) * 2018-08-09 2021-03-04 F. Hoffmann-La Roche Ag Determination of parkinson's disease
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
JP2022529344A (ja) * 2019-04-18 2022-06-21 エイシー イミューン ソシエテ アノニム 治療及び診断のための新規分子
KR102466943B1 (ko) * 2020-04-02 2022-11-14 한국과학기술연구원 갭을 갖는 바이오 센서를 이용한 파킨슨병 모니터링 방법 및 시스템
CN111537738A (zh) * 2020-05-18 2020-08-14 南通大学附属医院 用于超早期帕金森病检测的试剂盒
WO2023034914A2 (en) * 2021-09-01 2023-03-09 Vaxxinity, Inc. Methods for the prevention and treatment of synucleinopathies
CA3230055A1 (en) 2021-09-16 2023-03-23 Josefine Nielsen Soderberg Compositions and methods for treating synucleinopathies

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1512203A (en) 1974-05-08 1978-05-24 Aspin F Rolls for use in profiling film
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE98020T1 (de) 1986-12-15 1993-12-15 British Tech Group Usa Monomere phthalocyanin-reagenzien.
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
CA2415179A1 (en) 2000-07-07 2002-01-17 Panacea Pharmaceuticals, Inc. Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
WO2003000714A2 (en) 2001-06-22 2003-01-03 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
HUE035044T2 (en) 2003-05-19 2018-05-02 Prothena Biosciences Ltd Truncated fragments of alpha-synuclein in Lewy-body disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP2006031250A (ja) 2004-07-14 2006-02-02 Fuji Xerox Co Ltd 通信装置およびその制御方法
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
US20060205024A1 (en) 2005-03-08 2006-09-14 Sun Health Research Institute Method to diagnose and evaluate progression of Alzheimer's disease
WO2007011907A2 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
JP5525729B2 (ja) 2005-11-28 2014-06-18 ゲンマブ エー／エス 組換え一価抗体およびその作製方法
EP3067066B1 (en) 2007-02-23 2019-03-27 Prothena Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CA2678963C (en) 2007-02-23 2018-05-01 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US8454954B2 (en) * 2007-05-16 2013-06-04 The Brigham And Women's Hospital, Inc. Treatment of synucleinopathies
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
EP3470079A1 (en) 2008-04-29 2019-04-17 BioArctic AB Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
EP3521309A1 (en) * 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
BRPI1015472A2 (pt) 2009-04-09 2015-11-24 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central
HUE038313T2 (hu) * 2010-02-26 2018-10-29 Bioarctic Neuroscience Ab Protofibril-kötõ antitestek és alkalmazásuk Parkinson-kór, Lewy-testes demencia és más alfa-szinukleinopátiák terápiás és diagnosztikai eljárásaiban
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
GB201008682D0 (en) 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
ES2686550T3 (es) 2010-10-11 2018-10-18 Biogen International Neuroscience Gmbh Anticuerpos anti-tau humanos
TR201815563T4 (tr) * 2011-06-23 2018-11-21 Biogen Int Neuroscience Gmbh Anti-alfa sinüklein bağlayıcı moleküller.
JP2013059866A (ja) 2011-09-12 2013-04-04 Seiko Epson Corp 液体噴射装置、液体噴射装置の制御方法および液体噴射装置の制御プログラム
ES2937409T3 (es) * 2011-10-28 2023-03-28 Prothena Biosciences Ltd Anticuerpos humanizados que reconocen la alfa-sinucleína
KR102494798B1 (ko) 2012-07-03 2023-02-06 워싱턴 유니버시티 Tau에 대한 항체
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
EP3071597B1 (en) * 2013-11-21 2020-07-29 F.Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
US9732148B2 (en) 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
CN107949386A (zh) 2015-05-07 2018-04-20 阿速万科学有限责任公司 治疗神经退行性疾病的组合物和方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
KR102499438B1 (ko) 2016-06-02 2023-02-14 메디뮨 리미티드 알파-시누클레인에 대한 항체 및 이의 용도
KR102593669B1 (ko) 2016-11-15 2023-10-25 하. 룬드벡 아크티에셀스카브 시누클레인병증의 치료를 위한 제제, 용도 및 방법
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation

Also Published As

Publication number Publication date
US20230312693A1 (en) 2023-10-05
MY194944A (en) 2022-12-27
JP2018529634A (ja) 2018-10-11
TN2018000005A1 (en) 2019-07-08
IL256501B (en) 2021-10-31
US11524995B2 (en) 2022-12-13
JP2021191763A (ja) 2021-12-16
JP7138322B2 (ja) 2022-09-16
US10364285B2 (en) 2019-07-30
US20180127492A1 (en) 2018-05-10
DOP2018000013A (es) 2018-04-15
RU2017145653A (ru) 2019-08-13
RU2017145653A3 (es) 2019-11-21
US20180179271A1 (en) 2018-06-28
EA036499B1 (ru) 2020-11-17
CO2017012941A2 (es) 2018-03-09
US20190367594A1 (en) 2019-12-05
US10358483B2 (en) 2019-07-23
CR20180021A (es) 2018-03-13
JO3692B1 (ar) 2020-08-27
MA42439A (fr) 2018-05-23
AU2016292896B2 (en) 2022-02-24
IL256501A (en) 2018-02-28
EA201792616A1 (ru) 2018-06-29
WO2017009312A1 (en) 2017-01-19
CR20230300A (es) 2023-08-25
AR105336A1 (es) 2017-09-27
US10800836B2 (en) 2020-10-13
US20180179270A1 (en) 2018-06-28
US10358484B2 (en) 2019-07-23
CL2018000075A1 (es) 2018-05-11
US20190367595A1 (en) 2019-12-05
RU2765303C2 (ru) 2022-01-28
AU2016292896A1 (en) 2018-01-18
TWI729992B (zh) 2021-06-11
US20180127491A1 (en) 2018-05-10
JP7012004B2 (ja) 2022-02-10
PE20181049A1 (es) 2018-07-03
US10640554B2 (en) 2020-05-05
SV2018005612A (es) 2018-07-20
ECSP18002645A (es) 2018-03-31
US20190382473A1 (en) 2019-12-19
US20210061892A1 (en) 2021-03-04
UA125501C2 (uk) 2022-04-13
US20210054057A1 (en) 2021-02-25
ZA201708607B (en) 2019-05-29
US10647764B2 (en) 2020-05-12
HK1254358A1 (zh) 2019-07-19
GEP20207151B (en) 2020-09-25
US20170015739A1 (en) 2017-01-19
TW201716440A (zh) 2017-05-16
US10647763B2 (en) 2020-05-12
US11542323B2 (en) 2023-01-03
US20210147522A1 (en) 2021-05-20
KR20180029205A (ko) 2018-03-20
CN107709361A (zh) 2018-02-16
EP3322722A1 (en) 2018-05-23
JP2022174131A (ja) 2022-11-22
MX2018000504A (es) 2018-04-30
US10358482B2 (en) 2019-07-23
BR112017027506A2 (pt) 2018-09-11
US11421024B2 (en) 2022-08-23
PH12018500016A1 (en) 2018-07-09
CA2989735A1 (en) 2017-01-19
CN115925921A (zh) 2023-04-07
GB201512203D0 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
ECSP18002645A (es) Agentes, usos y métodos para el tratamiento de la sinucleinopatía
CO2019004755A2 (es) Agentes, usos y métodos para el tratamiento de la sinucleinopatía
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
GT201700072A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
EA201691582A1 (ru) Новые фармацевтические препараты
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
SV2017005486A (es) Anticuerpos a tau y usos de los mismos
CO2017003279A2 (es) Compuestos y composiciones farmacéuticamente aceptables de los mismos, eficaces como inhibidores de mk2
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
EA201991997A1 (ru) Комбинированная терапия
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
SG10201908881PA (en) Fused bicyclic compounds for the treatment of disease
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
PE20180691A1 (es) Variantes de il-37
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
EA201791937A1 (ru) Противовоспалительные полипептиды
IT201700104446A1 (it) Compositions, uses and methods for treatment of infertility and subfertility
EA201991866A1 (ru) Комбинированная терапия